Cytology before any antimicrobial is non-negotiable — it confirms pyoderma, identifies the dominant organism, and determines whether topical therapy alone is sufficient before a single antibiotic is prescribed.Veterinary Derm…+1
Topical antimicrobial therapy alone is the treatment of choice for surface and superficial pyoderma. Systemic antimicrobials should be reserved for deep pyoderma and for superficial pyoderma that has failed topical therapy.Veterinary Derm…+1 Chlorhexidine-based products remain highly effective against multidrug-resistant (MDR) organisms including methicillin-resistant Staphylococcus pseudintermedius (MRSP), and resistance remains low even with extended use.Journal of the… Benzoyl peroxide and ethyl lactate are additional topical options with established low-resistance profiles.Journal of the…
When systemic therapy is warranted, the first-choice drugs are clindamycin, first-generation cephalosporins (cefalexin, cefadroxil), and amoxicillin-clavulanate, selected on the basis of expected efficacy against the majority of meticillin-susceptible S. pseudintermedius.Journal of the…+1 Clindamycin is dosed at 11 mg/kg PO q12h [22 mg/kg/day total]; the lower approved label dose of 5.5 mg/kg q12h has shown efficacy in some studies, but dermatologist consensus supports the 11 mg/kg q12h dose based on area-under-the-curve/MIC pharmacodynamic targets.Journal of the… For all drugs outside the first-choice list — including third-generation cephalosporins and fluoroquinolones — culture and susceptibility testing must confirm susceptibility and exclude safer alternatives before use.Veterinary Derm…
Treatment duration is 2 weeks initial systemic therapy for superficial pyoderma and 3 weeks for deep pyoderma, followed by re-examination to assess progress and address primary causes.Veterinary Derm…+1 Extended therapy beyond clinical cure increases the risk of selecting methicillin-resistant strains; dogs treated with longer β-lactam courses are more likely to have methicillin-resistant S. pseudintermedius on recurrence than those treated for shorter durations.Journal of the…
Culture and susceptibility testing is essential for rationalising systemic therapy, particularly for deep pyoderma, recurrent cases, and any case where first-choice drugs are not appropriate.Veterinary Derm…+1 When interpreting culture results, Staphylococcus species identity and susceptibility are reliable and reproducible across laboratories, but additional non-staphylococcal organisms reported vary considerably between labs and may drive selection of unnecessarily broad-spectrum antibiotics — cytology should always be used to contextualise culture findings.Journal of Smal…
Fluoroquinolones and third-generation cephalosporins are second-choice drugs and should not be used empirically. Fluoroquinolone resistance rates in S. canis isolated from deep pyoderma lesions are 38–59%, and veterinarians selecting quinolones empirically for 63% of cases represents a significant stewardship failure.BMC Veterinary… Fluoroquinolones should be prescribed only when culture demonstrates no safer alternative.Journal of the… Prior fluoroquinolone and cephalosporin use is a known risk factor for selecting MRSP.Journal of the…
For S. canis-associated deep pyoderma specifically, 94% of strains retain sensitivity to penicillins, and β-lactamase-inhibiting penicillins are the current treatment of choice for the minority of penicillin-resistant strains with confirmed β-lactamase activity.BMC Veterinary… Clonal complex 13 (CC13) is a pathogenic cluster associated with high-level resistance including vancomycin and linezolid, and warrants culture-guided management.BMC Veterinary…
Proactive topical antiseptic therapy is recommended to prevent recurrences, and identifying and correcting the underlying primary cause driving pyoderma is essential to avoid repeated antibiotic courses and progressive resistance selection.Veterinary Derm…+1
| Drug | Dose/Protocol | Role | Key Caveat |
|---|---|---|---|
| Clindamycin | 11 mg/kg PO q12h | First-choice systemic | AUC/MIC target requires q12h dosing |
| Cefalexin / Cefadroxil | First-generation cephalosporin | First-choice systemic | Culture required if MRSP suspected |
| Amoxicillin-clavulanate | First-choice systemic | First-choice systemic | β-lactamase-producing strains covered |
| Fluoroquinolones | Culture-guided only | Second-choice | Resistance 38–59% in S. canis; empiric use contraindicated |
| Third-generation cephalosporins | Culture-guided only | Second-choice | Risk factor for MRSP selection |
| Chlorhexidine (topical) | Minimum 5-min contact time | First-line for surface/superficial pyoderma | Resistance low even with extended use |
Would you like guidance on how to manage recurrent pyoderma in a dog already treated with multiple antibiotic courses?